Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Subunit influenza vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Subunit influenza vaccine | BIOLOGICAL | 0.5 mL single dose vaccine |
| Adjuvanted influenza vaccine | BIOLOGICAL | 0.5 mL single dose vaccine |
| Adjuvanted influenza vaccine combined with CpG7909 | BIOLOGICAL | 0.5 ml influenza vaccine combined with 10 mcg of CpG7909 |
| Adjuvanted influenza vaccine combine with CpG7909 | BIOLOGICAL | 0.5 mL single dose vaccine combined with 30 mcg of CpG7909 |
Inclusion Criteria: * Healthy subjects aged 18 to ≤40 years Exclusion Criteria: * Any serious disease, hypersensitivity to egg or vaccine components, neurological symptoms or positive antibody test against dsDNA, RF, ANA or thyroid. * Abnormal TSH from blood samples collected during the screening...
Subunit influenza vaccine is used for influenza infection. It is an investigational vaccine being developed by Novartis AG for the prevention of influenza. The vaccine is currently in Phase 1 clinical development, meaning it is still being tested in early-stage trials to evaluate its safety and immunogenicity.
Subunit influenza vaccine is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS. The vaccine is currently in Phase 1 clinical development for the prevention of influenza infection.
Subunit influenza vaccine is in Phase 1 clinical development. It is an investigational vaccine for influenza infection and is not yet approved for public use. The Phase 1 trial has been completed, and the vaccine is still in the early stages of clinical testing.
Subunit influenza vaccine has been studied in one completed Phase 1 clinical trial, identified as NCT00559975. The trial was titled 'Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine' and enrolled 60 participants in Switzerland. The study was active-controlled and included healthy volunteers aged 18 years and older.
Subunit influenza vaccine is not FDA approved. It is an investigational vaccine currently in Phase 1 clinical development for influenza infection. The vaccine has completed one Phase 1 trial, but it has not yet received regulatory approval and remains in clinical testing.